GenIP, the artificial intelligence-enabled innovation intelligence Business quoted on AIM and included in the FTSE AIM All Share Index, is trying to turn rapid client growth into a sustainable business. Its audited results for 2025, published on 27 May 2026, showed Revenue more than quadrupling from a low base, although losses continued and auditors flagged a material uncertainty over going concern. The company has since published a half-year report for the six months to 30 June 2026, but its detailed figures could not be confirmed against the original announcement for this article, so they are not reported here.

What the company does

GenIP helps universities, government agencies, corporates, venture funds and research organisations evaluate, prioritise and commercialise new technologies. Its Invention Intelligence product suite, which produced almost all 2025 revenue, includes AI-driven market reports such as Invention Evaluator, Competitive Intelligence, Invention Prioritizer and Invention Validator. It also offers commercialisation services, including executive recruitment under the GenIP Talent Search brand, formerly Vortechs, along with venture and partner intelligence, virtual technology transfer office support and innovation training.

The business has close links with Tekcapital. GenIP acquired the Invention Evaluator and Vortechs Assets from Tekcapital entities in June 2024, and Tekcapital Europe held 53.86% of the shares according to the 2025 annual report. The company said it completed its separation from the Tekcapital group during 2025.

Latest developments

On 28 April 2026 GenIP announced a reciprocal sales alliance with Cardinal Intellectual Property in the United States, and in early May 2026 it announced a share placing to raise £350,000. That followed a £300,000 raise in December 2025. The company also issued an announcement on new orders in May 2026. In its results it highlighted new markets including Saudi Arabia, Singapore, Brazil, Chile, the United Kingdom and Australia, and partnerships with a Chilean green technology platform and a Brazilian technology park.

GenIP said active clients grew by more than 225% year on year across 25 countries in 2025. Notable work included a programme in Saudi Arabia worth about US$350,000 and a contract with Brazil's National Nuclear Energy Commission.

Financial and Dividend picture

For the year to 31 December 2025, revenue rose 323% to about US$520,000 from roughly US$123,000. Gross Profit was about US$165,000, giving a Margin of around 32%, and the adjusted EBITDA loss was about US$1.04m. Cash fell to about US$661,000 from US$972,000, and net assets were about US$579,000. The company said early 2026 trading was consistent with the previous year, noting that academic clients tend to contract in the second half. Management said it expects margins to improve as higher-value products make up a larger share of sales. No dividend is paid.

Sector and index context

Demand for AI tools that speed up technology assessment is growing, but the market is competitive and budgets in academia and government can be uneven. Within the FTSE AIM All Share Index, GenIP is among the smallest technology names, with a Market Value that leaves little margin for disappointment.

Key risks

The main risks are the Going Concern uncertainty, dependence on further fundraising, lumpy contract timing, reliance on a limited number of larger contracts and the challenge of improving margins. A controlling Shareholder may also limit Liquidity in the shares.

What to watch next

Investors will look for second-half contract wins, especially from academic clients, evidence of margin gains from higher-value products, the results of corporate and Asian sales expansion, and any further Capital raising.